We're taking a closer look at Qiagen today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 5.6%. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.
-
Qiagen has moved -15.3% over the last year compared to 18.7% for the S&P 500 -- a difference of -34.0%
-
QGEN has an average analyst rating of buy and is -12.36% away from its mean target price of $50.82 per share
-
Its trailing 12 month earnings per share (EPS) is $1.49
-
Qiagen has a trailing 12 month Price to Earnings (P/E) ratio of 29.9 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $2.2 and its forward P/E ratio is 20.2
-
QGEN has a Price to Earnings Growth (PEG) ratio of 12.05, which shows the company is potentially overvalued when we factor growth into the price to earnings calculus.
-
The company has a Price to Book (P/B) ratio of 2.67 in contrast to the S&P 500's average ratio of 2.95
-
Qiagen is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
-
Qiagen has on average reported free cash flows of $336.58 Million over the last four years, during which time they have grown by an an average of 21.3%